CSF3 and small cell lung carcinoma: In this retrospective pooled analysis of data from three global, independent, randomized, double‐blind, placebo‐controlled, multicenter phase 2 trials in patients with ES‐SCLC, administering trilaciclib prior to chemotherapy significantly reduced DSN in cycle 1 and occurrence of SN across cycles 1 to 4 regardless of G‐CSF administration.